All In Biotech

Drug Trial Radar · NCT06236308

TTAX03 for the Treatment of Lumbosacral Facet Joint Pain

A Randomized, Phase 1 Dose Finding Study of TTAX03 for the Treatment of Lumbosacral Facet Joint Pain

Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jul 15, 2024

Primary completion

Jan 31, 2025

Study completion Mar 4, 2025

Sponsor

Lead sponsor
BioTissue Holdings, IncIndustry
Sponsor type
Industry
First posted
Feb 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 35 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a pilot study examining the safety and efficacy of a single intra-articular (IA) injection of TTAX03 per joint to relieve severe spinal facet joint (FJ) pain and improve function in subjects with facet joint pain (FJP) in the lumbosacral region. The design is randomized, double blinded, placebo controlled and dose-group sequential.

Conditions

  • Facet Joint Pain

Interventions

  • TTAX03 10mgBiological

    TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.

  • TTAX03 25mgBiological

    TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.

  • Placebo Comparator: Control SalineBiological

    2 mL Sterile, preservative free 0.9% NaCl

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Physical, functional and physiological responses to the intervention, as well as unanticipated eventsTime frame: 12-weeks post baseline

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.